Novo Nordisk and GoodRx recently announced a partnership aimed at making Ozempic and Wegovy products more affordable for cash-paying patients.
Starting this week, customers can buy Novo Nordisk’s Semaglutide Pen products for $499 a month through GoodRx. Typically, these medications, such as Ozempic, cost over $1,000 without insurance.
“The demand for GLP-1 medications is at an all-time high, yet many Americans encounter difficulties in accessing them,” noted Wendy Barnes, CEO and President of GoodRx, in a statement.
She added, “By collaborating with Novo Nordisk, we are making significant strides in increasing access to treatments from these innovative brands for millions who need them. This exemplifies how the GoodRx platform can provide savings broadly and address coverage gaps, ensuring that more individuals receive the care they require.”
This partnership is part of Novo Nordisk’s efforts to enhance the availability of popular medications for diabetes and weight loss.
Earlier this year, the company unveiled a direct patient initiative, Novocare® Pharmacy, for those who are uninsured and can pay $499 monthly for Wegovy. Novo Nordisk has also teamed up with online telehealth services like RO and LifeMD to offer pens at similar price points.
Initially, Hims & Hers was involved in this collaboration, but it ended after accusations that the combined version of Semaglutide was being sold illegally. Hims & Hers contends it adheres to regulatory standards for its personalized composite products.
“Our mission centers on improving access to effective FDA-approved treatments, and partnering with GoodRx enables us to connect with individuals looking for savings and support through a trusted platform,” said Dave Moore, executive vice president of US operations at Novo Nordisk.
He also mentioned that this initiative supports a new Ozempic® Self-Pay option for type 2 diabetes patients at unprecedented prices, catering to GoodRx patients who require genuine GLP-1 medications.
Senator Bernie Sanders (I-Vt.), known for his criticism of high drug prices, described the announcement as a “small step.”
He remarked, “The Novo Nordisk decision to reduce the Ozempic price to $499 for uninsured individuals is a modest move, but let’s not forget that in Germany, Ozempic costs just $59, with production costs under $5. The US should not endure the highest prescription drug prices worldwide.”
